Clinical trial
A Phase 2 Double Blind Placebo Controlled Study on the Efficacy of Bumetanide for Cognitive Improvement in Children and Adolescents With Down Syndrome
NCT06465823 is registered in ClinicalTrials.gov with Stefano Vicari as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double Blind Placebo Controlled Study on the Efficacy of Bumetanide for Cognitive Improvement in Children and Adolescents With Down Syndrome
- Lead sponsor
- Stefano Vicari
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 11, 2023
- Completion date
- September 30, 2026
- Enrollment
- 64 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.